胸苷激酶1和生存素在甲状腺癌及腺瘤组织的表达及其临床意义  

Expression and clinical significance of thymidine kinase 1 and Survivin in thyroid carcinoma and thyroid benign tumor

作　　者：陈胜武[1] 刘言[2] 冯长生[1] 张丽娟[1] 谢锐 Chen Shengwu;Liu Yan;Feng Changsheng;Zhang Lijuan;Xie Rui(Department of Head and Neck Surgery, Otorhinolaryngology, Daqing Longnan Hospital (Qiqihar Medical School No.5 Affiliated Hospital), Daqing 163453, China;Department of Pathology, Daqing Longnan Hospital (Qiqihar Medical School No.5 Affiliated Hospital), Daqing 163453, China;Teaching and Research Section of Surgery, Guangdong Medical University, Zhanjiang 524023, China)

机构地区：[1]大庆市龙南医院(齐齐哈尔医学院第五附属医院)头颈外、耳鼻喉科,163453 [2]大庆市龙南医院(齐齐哈尔医学院第五附属医院)病理科,163453 [3]广东医科大学外科学教研室,湛江524023

出　　处：《中华实验外科杂志》2019年第2期301-303,共3页Chinese Journal of Experimental Surgery

摘　　要：目的 探讨甲状腺癌及腺瘤组织中胸苷激酶1(TK1)和生存素(Survivin)的表达及临床意义。方法 收集行手术治疗的107例甲状腺肿瘤患者的组织标本,包括24例甲状腺瘤、83例甲状腺癌组织,另取15例正常甲状腺组织作为对照组;采用免疫组织化学法检测各组织中TK1和Survivin的表达水平。结果 TK1在正常甲状腺组织、甲状腺瘤组织和甲状腺癌组织中的表达率分别为6.67%(1/15)、41.67%(10/24)和67.47%(56/83),两两之间比较差异有统计学意义(分别为t=5.244、19.301、5.584,P<0.05),TK1表达水平与甲状腺癌美国肿瘤联合委员会(AJCC)分期、颈部淋巴结转移、包膜浸润明显相关(分别为t=4.329、4.506、4.747,P<0.05);Survivin在正常甲状腺组织、甲状腺瘤组织和甲状腺癌组织中的表达率分别为6.67%(1/15)、37.50%(9/24)和61.45%(51/83),两两之间比较差异有统计学意义(分别为t=4.334、15.306、4.603,P<0.05),Survivin表达水平与甲状腺癌AJCC分期、组织分化、颈部淋巴结转移、包膜浸润明显相关(分别为t=6.295、8.967、6.116、6.005,P<0.05)。结论 TK1和Survivin在甲状腺癌组织中高表达、是甲状腺癌的不良预后因素;检测TK1和Survivin有助于判断甲状腺癌浸润转移潜能。Objective To investigate the expression of thymidine kinase 1 (TK1) and Survivin in thyroid carcinoma and thyroid benign tumor, and to analyze the clinical significance.Methods The tissue samples of 107 patients with thyroid tumor who underwent surgical resection were collected, including 24 cases of thyroid benign tumor tissues, 83 cases of thyroid carcinoma tissues, and 15 cases of thyroid normal tissues selected as the control group;Immunohistochemical method staining for the paraffin sections(SP method)were used to assess the expression of TK1 and Survivin expression in thyroid carcinoma tissues, thyroid benign tumor tissues and thyroid normal tissues.Results The expression rate of TK1 in thyroid normal tissues, thyroid benign tumor tissues and thyroid carcinoma tissues were 6.67% (1/15), 41.67% (10/24) and 67.47% (56/83) with significant difference (Respectively, t=5.244, 19.301, 5.584, P<0.05), the expressions of TK1 were related thyroid carcinoma to American Joint Committee on Cancer (AJCC) clinical stage, lymph node metastasis and the degree of infiltration (Respectively, t=4.329, 4.506, 4.747, P<0.05);the expression rate of Survivin in thyroid normal tissues, thyroid benign tumor tissues and thyroid carcinoma tissues were 6.67% (1/15), 37.50% (9/24) and 61.45% (51/83) with significant difference (Respectively, t=4.334, 15.306, 4.603, P<0.05), the expressions of Survivin were related thyroid carcinoma to AJCC clinical stage, differentiation degree, lymph node metastasis and the degree of infiltration (Respectively, t=6.295, 8.967, 6.116, 6.005, P<0.05).Conclusion TK1 and Survivin are highly expressed in thyroid carcinoma tissues, TK1 and Survivin are prognostic factor for thyroid carcinoma patients;Detecting the expressive levels of TK1 and Survivin in thyroid carcinoma have certain reference value for judging invasion and metastasis potential of patients of thyroid carcinoma.

关 键 词：胸苷激酶1 生存素 甲状腺癌 免疫组织化学法 

分 类 号：R736.1[医药卫生—肿瘤]